Skip to main content
4th of July Sale — Get 40% off Vantage subscriptions
Get Started
SubscribeLogin
Published • loading... • Updated

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Summary by Journal Gazette & Times-Courier
Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)EPCORE DLBCL-4 demonstrated improved…

3 Articles

Journal Gazette & Times-CourierJournal Gazette & Times-Courier
Center

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Topline results from Phase 3 EPCORE® DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)EPCORE DLBCL-4 demonstrated improved…

Read Full Article
endpoints.newsendpoints.news

AbbVie and Genmab's latest win brings Epkinly closer to label expansion

AbbVie and Genmab’s bispecific antibody Epkinly succeeded in combination with a widely used cancer drug, bringing it one step closer to a potential label expansion in diffuse large B-cell lymphoma. In the US, Epkinly and ...

Read Full Article
borsen.dkborsen.dk

Genmab Shows Positive Data in the Treatment of Large B-Cell Lymphoma

Genmab shows positive data in the treatment of large B-cell lymphomaGenmab has had positive results in a phase 3 study with the cancer treatment epcoritamab in combination with lenalidomide in the treatment of large B-cell lymphoma.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
4th of July SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Journal Gazette & Times-Courier broke the news on Monday, June 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

AbbVie icon

AbbVie

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal